Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: results of trial on prostate cancer drug

( - On Friday Roche announced that the IPATential150 Phase III trial met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with metastatic castration-resistant metastatic prostate cancer (mCRPC) with PTEN loss tumours.

In this group of patients, ipatasertib, in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to the current standard of care (abiraterone and prednisone/prednisolone) plus placebo.

The other co-primary endpoint of rPFS in the overall study population (ITT) was not met.

The results of the IPATential150 study will be presented at an upcoming medical meeting. The trial will continue until the next planned analysis and data will be shared with health authorities.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.